Demonstrating the reliability of in vivo metabolomics-based chemical grouping: Part 2 – Consistency of group-specific metabolic effects - Scorecard - MDSpire
Clinical Scorecard: Assessing the Reliability of In Vivo Metabolomics-Based Chemical Grouping: Part 2—Consistency of Metabolic Effects Within Groups
At a Glance
Category
Detail
Condition
Consistency and toxicological interpretation of metabolomics-based chemical effect groups
Key Mechanisms
Metabolite and lipid response profiles are assessed for consistency across laboratories and interpreted using metabolomic associative events (mAEs) within the Adverse Outcome Pathway framework.
Target Population
Female and male rats exposed to test chemicals; the study evaluates metabolomics data rather than a patient population.
Care Setting
Regulatory toxicology and chemical safety assessment, including evaluation of read-across and chemical grouping.
Key Highlights
The study examined whether metabolic responses underlying three effect groups were consistent across five ring-trial partners, with female and male rats analysed separately.
The effect groups were linked to androgen receptor activity, peroxisome proliferation, and anaemia.
Partners identified discriminatory metabolic features and annotated metabolites using their preferred methods.
The study assessed whether metabolite profiles could be interpreted using literature- and pathway-database-derived mAEs.
The stated aim included improving mAE detection specificity by integrating toxicological knowledge with reproducibility of metabolite detection and directional changes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Chemical grouping hypotheses based mainly on structural resemblance may lack adequate evidence of shared biological effects.
Metabolomics interpretation is challenged by metabolite annotation difficulties, insufficient standardisation, and incomplete understanding of metabolite and lipid roles in toxicity mechanisms.
Data quality should be assessed before metabolomics data are used for grouping, as reported in the preceding MATCHING project.
Patient & Prescribing Data
Not applicable; this is a regulatory toxicology study using rat plasma metabolomics data.
The preceding MATCHING study used plasma from rats exposed to one of eight test substances at high or low doses for 28 days. This article evaluates consistency and interpretation of metabolic responses; it does not provide patient treatment or prescribing information.
Clinical Best Practices
Assess metabolomics data quality before using the data to support chemical grouping.
Interpret discriminatory metabolite profiles in the context of an explicit adverse-outcome hypothesis and relevant mAEs.
Use toxicological interpretation alongside statistical evidence when evaluating metabolomics-based chemical groups.
Consider reproducibility of metabolite detection and directional changes across laboratories when evaluating mAE specificity.
by G. R. Lloyd, C. Sands, A. Kende, V. Haake, E. Amstalden, M. Bouhifd, T. Ebbels, F. Lai, P. E.G. Leonards, U. Simanainen, T. Sobanski, A. D. Southam, L. Swindale, R. J. M. Weber, F. M. Zickgraf, H. Kamp, M. R. Viant
